Secondary stroke prevention—personalized antiplatelet therapy

被引：0
作者：
David Tanne
机构：
[1] Sagol Neuroscience Center,
[2] Chaim Sheba Medical Center and Sackler Faculty of Medicine,undefined
[3] Tel Aviv University,undefined
来源：
Nature Reviews Neurology | 2012年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
High platelet reactivity persists in many patients receiving antiplatelet therapy for secondary prevention of ischaemic stroke. Patient-tailored antiplatelet therapy, guided by platelet function tests, is an appealing approach for prevention of recurrent vascular events. However, a recent study has demonstrated that this strategy is associated with worse clinical outcomes.
引用
收藏
页码：536 / 537
页数：1
相关论文
共 16 条
  • [1] Snoep JD(2007)Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis Arch. Intern. Med. 167 1593-1599
  • [2] Hovens MM(2008)Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome Cerebrovasc. Dis. 25 355-361
  • [3] Eikenboom JC(2007)Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis Am. Heart J. 154 221-231
  • [4] van der Bom JG(2010)Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis J. Thromb. Haemost. 8 923-933
  • [5] Huisman MV(2012)Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the antiplatelet drug resistances and ischemic events study Circulation 125 3201-3210
  • [6] Schwammenthal Y(2012)High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial) J. Am. Heart Assoc. 1 e000703-1105
  • [7] Snoep JD(2011)Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 1097-337
  • [8] Combescure C(2004)Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial Lancet 364 331-1413
  • [9] Reny JL(2012)Vorapaxar in the secondary prevention of atherothrombotic events N. Engl. J. Med. 366 1404-undefined
  • [10] Pettersen A-Å(undefined)undefined undefined undefined undefined-undefined
12